FDA Issues Voluntary Recall of Duloxetine Due to Carcinogenic Impurities
The FDA has issued a voluntary recall of the antidepressant duloxetine due to carcinogenic impurities, specifically N-nitroso-duloxetine. Rising Pharmaceuticals initiated the recall affecting over 233,000 bottles, highlighting ongoing concerns about nitrosamine contamination in medications. Patients are advised to consult healthcare providers for guidance and alternative treatment options. Stay informed about medication safety and recalls to protect your health.
FDA Issues Class II Recall for Duloxetine Capsules Over Health Concerns
The FDA has issued a Class II recall for over 7,100 bottles of Duloxetine Delayed-Release Capsules due to elevated levels of a harmful chemical, N-nitroso-duloxetine. Patients are urged to consult healthcare professionals before making any changes to their medication. This recall highlights the FDA’s commitment to drug safety and public health.